Official Title
Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study
Brief Summary

The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.

Detailed Description

Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized
patients with severe pneumonia requiring oxygen supply and followed up for 6 months after
hospital discharge (see primary and secondary outcomes).

Secondary objectives

To describe pulmonary sequelae according to :

- the unit in which the patient was hospitalized,

- the maximum oxygen flow rate required during hospitalization,

- McCabe score,

- age,

- tobacco consumption,

- biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),

- number of days from onset of symptoms to hospitalization,

- co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild
to moderate COPD/respiratory failure, overweight),

- concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids,
immunosuppressants, ACE inhibitors)

- specific drug treatments administered to treat COVID-19 infection,

- non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment)
to manage respiratory disorders of COVID-19 infection.

To assess the impact of factors of social inequality on the severity of COVID-19 infection.

Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2
SARS infection will be seen in consultation at approximately 3 and 6 months after hospital
discharge, as per standard practice.

Completed
COVID19
Dyspnea
Eligibility Criteria

Inclusion criteria:

- Age ≥ 18 years old

- SARS-CoV-2 infection proven by RT-PCR and/or retrospective serology and/or a COVID-19
syndrome with evocative chest CT scan

- Hospitalized for severe pneumonia due to SARS-CoV-2 infection requiring oxygen supply

Exclusion criteria:

- Not hospitalized for a severe COVID-19 infection

- Absence of respiratory symptoms at V1 (3 months after hospital discharge), defined as:
absence of residual exertional dyspnea and persistent pulmonary infiltrates on
follow-up chest radiography at 1 month (if available), transcutaneous oxyhemoglobin
saturation >94% and normal pulmonary auscultation

- Patient with pre-existing chronic lung disease prior to the first episode of COVID-19:
chronic obstructive pulmonary disease confirmed by respiratory function testing with a
forced expiratory volume in one second (FEV1) < 50% and/or a diffusing capacity for
carbon monoxide (DLCO) < 60%, fibrotic lung disease or chronic respiratory failure (on
long-term oxygen therapy)

- Opposition to participation in the study

- Patient under legal protection

- Patient not affiliated to/beneficiary of a social security scheme

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace
Mulhouse, Alsace, France

Centre Hospitalier de la Côte Basque - Bayonne
Bayonne, France

Centre Hospitalier Métropole Savoie
Chambéry, France

Centre Hospitalier Colmar
Colmar, France

Centre Hospitalier Douai
Douai, France

Centre Hospitalier de Dunkerque
Dunkerque, France

Centre Hospitalier Départemental Vendée - La Roche sur Yon
La Roche-sur-Yon, France

Centre Hospitalier du Mans
Le Mans, France

Centre Hospitalier Robert Boulin - Libourne
Libourne, France

Centre Hospitalier Annecy Genevois
Metz-Tessy, France

Centre Hospitalier Régional Metz-Thioville
Metz, France

Centre Hospitalier Le Raincy Montfermeil
Montfermeil, France

Centre Hospitalier Régional Orléans
Orléans, France

Centre Hospitalier de Soissons
Soissons, France

George-Daniel Calcaianu, MD, Principal Investigator
GHRMSA hospital

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
NCT Number
Keywords
COVID19
PNEUMOPATHY
dyspnea
MeSH Terms
COVID-19
Dyspnea